Pure Biologics Past Earnings Performance
Past criteria checks 0/6
Pure Biologics's earnings have been declining at an average annual rate of -48.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 35.5% per year.
Key information
-48.4%
Earnings growth rate
-39.0%
EPS growth rate
| Biotechs Industry Growth | 56.3% |
| Revenue growth rate | -35.5% |
| Return on equity | -243.6% |
| Net Margin | -29,097.2% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
Here's Why We're Watching Pure Biologics Spólka Akcyjna's (WSE:PUR) Cash Burn Situation
Dec 06
We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business Growth
Aug 14Will Pure Biologics Spólka Akcyjna (WSE:PUR) Spend Its Cash Wisely?
Apr 30We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business Growth
Jan 03We're Interested To See How Pure Biologics Spólka Akcyjna (WSE:PUR) Uses Its Cash Hoard To Grow
Apr 21Revenue & Expenses BreakdownBeta
How Pure Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -32 | 38 | 0 |
| 30 Jun 23 | 0 | -31 | 34 | 0 |
| 31 Mar 23 | 1 | -26 | 30 | 0 |
| 31 Dec 22 | 1 | -26 | 29 | 0 |
| 30 Sep 22 | 1 | -19 | 26 | 0 |
| 30 Jun 22 | 1 | -17 | 24 | 0 |
| 31 Mar 22 | 0 | -15 | 22 | 0 |
| 31 Dec 21 | 0 | -12 | 21 | 0 |
| 30 Sep 21 | 0 | -15 | 29 | -13 |
| 30 Jun 21 | 0 | -14 | 27 | -8 |
| 31 Mar 21 | 0 | -13 | 24 | -4 |
| 31 Dec 20 | 1 | -12 | 20 | 0 |
| 30 Sep 20 | 1 | -9 | 8 | 16 |
| 30 Jun 20 | 1 | -7 | 7 | 15 |
| 31 Mar 20 | 2 | -6 | 4 | 16 |
| 31 Dec 19 | 2 | -4 | 5 | 12 |
| 30 Sep 19 | 2 | -3 | 6 | 9 |
| 30 Jun 19 | 2 | -2 | 5 | 6 |
| 31 Mar 19 | 2 | -1 | 8 | 0 |
| 31 Dec 18 | 1 | -1 | 6 | 0 |
| 30 Sep 18 | 1 | 0 | 4 | 0 |
| 31 Dec 17 | 1 | 0 | 1 | 0 |
| 31 Dec 16 | 1 | 0 | 1 | 0 |
Quality Earnings: PUR is currently unprofitable.
Growing Profit Margin: PUR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PUR is unprofitable, and losses have increased over the past 5 years at a rate of 48.4% per year.
Accelerating Growth: Unable to compare PUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: PUR has a negative Return on Equity (-243.59%), as it is currently unprofitable.